Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Simson Tsz Yat, Luk"'
Autor:
Chi Chun Wong, Jian-Lin Wu, Fenfen Ji, Wei Kang, Xiqing Bian, Huarong Chen, Lam-Shing Chan, Simson Tsz Yat Luk, Samuel Tong, Jiaying Xu, Qiming Zhou, Dabin Liu, Hao Su, Hongyan Gou, Alvin Ho-Kwan Cheung, Ka Fai To, Zongwei Cai, Jerry W. Shay, Jun Yu
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-15 (2022)
Looking for metabolic-associated vulnerabilities is a promising approach for therapeutic intervention in KRAS-mutant colorectal cancer. Here, the authors show that the cholesterol-uptake regulator PCSK9 drives tumourigenesis and is a therapeutic targ
Externí odkaz:
https://doaj.org/article/b983ec1445e54ade901f9b1e5f30d6ee
Autor:
Yun Qian, Lianxin Zhou, Simson Tsz Yat Luk, Jiaying Xu, Weilin Li, Hongyan Gou, Huarong Chen, Wei Kang, Jun Yu, Chi Chun Wong
Publikováno v:
Oncogene.
The incidence of colorectal cancer (CRC) is rising worldwide. Here, we identified SCNN1B as an outlier down-regulated in CRC and it functions as a tumor suppressor. SCNN1B mRNA and protein expression were down-regulated in primary CRC and CRC cells.
Autor:
Chi Chun Wong, Jian-Lin Wu, Fenfen Ji, Wei Kang, Xiqing Bian, Huarong Chen, Lam-Shing Chan, Simson Tsz Yat Luk, Samuel Tong, Jiaying Xu, Qiming Zhou, Dabin Liu, Hao Su, Hongyan Gou, Alvin Ho-Kwan Cheung, Ka Fai To, Zongwei Cai, Jerry W. Shay, Jun Yu
Publikováno v:
Nature communications. 13(1)
Therapeutic targeting of KRAS-mutant colorectal cancer (CRC) is an unmet need. Here, we show that Proprotein Convertase Subtilisin/Kexin type 9 (PSCK9) promotes APC/KRAS-mutant CRC and is a therapeutic target. Using CRC patient cohorts, isogenic cell
Autor:
Xiaoming Zhang, Jiaying Xu, Yun Qian, Enders Kw Ng, Huarong Chen, Liuyang Zhao, Jun Yu, Phlip Wy Chiu, Chi Chun Wong, Weilin Li, Simson Tsz Yat Luk, Wei Kang
Publikováno v:
Theranostics. 9:6256-6268
Rationale: Prostaglandin E2 (PGE2) is a pro-inflammatory eicosanoid up-regulated in gastric cancer (GC). However, its impact on epigenetic dysfunction in the process of gastric carcinogenesis is unknown. In this study, we investigate the role of PGE2
Autor:
Lam-Shing Chan, Chi Chun Wong, Wei Kang, Senji Shirasawa, Fenfen Ji, Huarong Chen, Simson Tsz Yat Luk, Jian-Lin Wu, Dabin Liu, Xiqing Bian, Jiaying Xu, Weilin Li, Yun Qian, Joseph J.Y. Sung, Qiming Zhou, Jun Yu, Hongyan Gou
Publikováno v:
Gastroenterology. 159(6)
Background & Aims Mutant KRAS promotes glutaminolysis, a process that uses steps from the tricarboxylic cycle to convert glutamine to α-ketoglutarate and other molecules via glutaminase and SLC25A22. This results in inhibition of demethylases and ep
Autor:
Joseph J Y, Sung, Olabisi Oluwabukola, Coker, Eagle, Chu, Chun Ho, Szeto, Simson Tsz Yat, Luk, Harry Cheuk Hay, Lau, Jun, Yu
Publikováno v:
Gut
Objective Helicobacter pylori is associated with gastric inflammation, precancerous gastric atrophy (GA) and intestinal metaplasia (IM). We aimed to identify microbes that are associated with progressive inflammation, GA and IM 1 year after H. pylori
Autor:
Chi Chun, Wong, Wei, Kang, Jiaying, Xu, Yun, Qian, Simson Tsz Yat, Luk, Huarong, Chen, Weilin, Li, Liuyang, Zhao, Xiaoming, Zhang, Phlip Wy, Chiu, Enders Kw, Ng, Jun, Yu
Publikováno v:
Theranostics
Rationale: Prostaglandin E2 (PGE2) is a pro-inflammatory eicosanoid up-regulated in gastric cancer (GC). However, its impact on epigenetic dysfunction in the process of gastric carcinogenesis is unknown. In this study, we investigate the role of PGE2
Autor:
Sung, Joseph J. Y., Coker, Olabisi Oluwabukola, Chu, Eagle, Chun Ho Szeto, Simson Tsz Yat Luk, Harry Cheuk Hay Lau, Jun Yu
Publikováno v:
Gut; Sep2020, Vol. 69 Issue 9, p1572-1581, 9p